Tracheotomy

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

Retrieved on: 
Monday, February 26, 2024

Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.

Key Points: 
  • Health Canada stated that a Request for Reconsideration can be filed within 30 days of receiving the NON/w.
  • The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the original submission.
  • AB Science provided a methodologically justified new claim “patients with ALS prior to any loss of function”, where CAFS and Overall Survival (OS) are significantly improved.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Retrieved on: 
Thursday, December 21, 2023

Plasma neurofilament light chain (NfL), a blood-based biomarker associated with neurodegeneration, declined by 16% (95% CI: 2% to 28%) from baseline to 76 weeks of treatment in the HEALEY ALS Platform Trial Open Label Extension (OLE) in participants randomized to CNM-Au8 30 mg relative to participants initially randomized to placebo (p=0.023).

Key Points: 
  • Plasma neurofilament light chain (NfL), a blood-based biomarker associated with neurodegeneration, declined by 16% (95% CI: 2% to 28%) from baseline to 76 weeks of treatment in the HEALEY ALS Platform Trial Open Label Extension (OLE) in participants randomized to CNM-Au8 30 mg relative to participants initially randomized to placebo (p=0.023).
  • CNM-Au8 was associated with a 10% relative reduction in plasma NfL over the 24-week double-blind treatment period of the HEALEY ALS Platform Trial (p=0.040).
  • The concordance of these long-term biomarker and survival results with previously reported clinical outcomes from two Phase 2 ALS trials is encouraging.
  • Additional biomarker and clinical data from the HEALEY ALS Platform Trial open-label extension periods have been collected and are undergoing analysis for expected results to be reported in the first quarter of 2024.”

Enlyte Announces Winners of 2023 Heart of Case Management Awards

Retrieved on: 
Wednesday, October 11, 2023

SAN DIEGO, Oct. 11, 2023 /PRNewswire/ -- Enlyte, a leader in cost-containment technology, provider networks, clinical services, pharmacy benefit management (PBM) and disability management, has announced the winners of the 2023 Heart of Case Management Awards, a prestigious honor recognizing four individuals nominated by their managers and selected from a field of more than 2,000 case managers across the country.

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 /PRNewswire/ -- Enlyte, a leader in cost-containment technology, provider networks, clinical services, pharmacy benefit management (PBM) and disability management, has announced the winners of the 2023 Heart of Case Management Awards, a prestigious honor recognizing four individuals nominated by their managers and selected from a field of more than 2,000 case managers across the country.
  • This was the case for this year's winners of Genex's Heart of Case Management Awards, who overcame overwhelming odds to help injured employees meet their recovery goals.
  • Among this year's winners is a case manager who used her critical thinking skills to allow an Amish builder to return to function following a spinal cord injury.
  • Nominees are judged on a multitude of criteria including expertise, excellence, adaptability, trust, influential communication, critical thinking and outcomes.

Robust Growth Projected for Global Tracheostomy Securement Tape Market in 2023 and Beyond - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 4, 2023

The "Tracheostomy Securement Tape Market Analysis, 2023 - Industry Trends, Market Size, Growth Opportunities, Market Share, Forecast by Types, Applications, Countries, and Companies, 2018 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tracheostomy Securement Tape Market Analysis, 2023 - Industry Trends, Market Size, Growth Opportunities, Market Share, Forecast by Types, Applications, Countries, and Companies, 2018 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Global Tracheostomy Securement Tape market is set for robust growth in 2023 and the years to come, as revealed by the latest industry report.
  • Titled "2023 State of the Tracheostomy Securement Tape Industry," this comprehensive analysis offers an in-depth exploration of Tracheostomy Securement Tape markets, providing valuable insights, trends, and strategic guidance for businesses, investors, and industry experts.
  • Leading Tracheostomy Securement Tape companies are strategically focusing on niche growth segments to drive revenue growth in the near to medium-term future.

Scivita Medical Single-use Broncho Videoscope Solution Showcased at ERS 2023

Retrieved on: 
Wednesday, September 13, 2023

ROME, Sept. 13, 2023 /PRNewswire/ -- Scivita Medical presented Single Broncho Videoscope Solution at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from 9-13 September 2023 (Booth D.03A).

Key Points: 
  • ROME, Sept. 13, 2023 /PRNewswire/ -- Scivita Medical presented Single Broncho Videoscope Solution at the European Respiratory Society (ERS) International Congress 2023, in Milan, Italy from 9-13 September 2023 (Booth D.03A).
  • Scvita Medical Single-use Broncho Videoscope Solution includes Single Use Broncho Videoscope and Full HD Visualization Endoscopic Image Processor, which meets respiratory surgeon's various clinic needs.
  • Besides, Scivita Medical Single-use Broncho Videoscope has 3 different sizes, offering more applications scenarios, including treatment and diagnosis.
  • Scivita Medical Single Use Broncho Videoscope is developed from the company's unique technology platform.

Mitsubishi Tanabe Pharma America Announces Post-Hoc Analysis Examining Effect of Early Intervention with RADICAVA® (edaravone) on Survival and Disease Progression Milestones in People with ALS

Retrieved on: 
Thursday, August 17, 2023

JERSEY CITY, N.J., Aug. 17, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a post-hoc analysis of the pivotal, Phase 3 study (MCI186-19) reviewing the effect of intravenous (IV) RADICAVA® (edaravone) on survival and additional disease progression milestone events in people with amyotrophic lateral sclerosis (ALS). Results from the analysis, which were published in Muscle & Nerve, suggest that timely and continued treatment with RADICAVA when initiated first was associated with a lower risk of death, tracheostomy, permanent assisted ventilation (PAV) or hospitalization, compared to people with ALS who received placebo first followed by RADICAVA.

Key Points: 
  • During the open-label period, there were two deaths in the EE group and four in the PE group.
  • As these results are from a post-hoc analysis, the results should be interpreted with caution.
  • Lastly, the MCI186-19 study was not powered a priori to analyze the novel composite endpoint of death, tracheostomy, PAV, or hospitalization.
  • "The findings of this post-hoc analysis are encouraging," said Benjamin Rix Brooks, M.D., a longtime leader in ALS research and lead author of the study.

Australia has had school nurses for more than 100 years – but we don't use them enough

Retrieved on: 
Wednesday, August 2, 2023

It specifically asks:

Key Points: 
  • It specifically asks:
    What can be done to establish stronger partnerships between schools, local health networks and primary health networks?
  • What can be done to establish stronger partnerships between schools, local health networks and primary health networks?

School nurses are real nurses

    • It’s a common misconception among students and staff that school nurses are not “real nurses”.
    • I come across this in my work with school nurses – people think nurses are only trained to work in hospitals, even though a large group specialise in working outside them.

What do they do?

    • The hours school nurses work and the work they do (even the job title they have) often depends on their employer.
    • Some school nurses primarily care for students with acute health issues such as illness or injury.
    • Beyond this, nurses can coordinate health care for boarding school students, or attend school camps and sporting events.

Health promotion and screening


    Some school nurses focus on health promotion and early interventions. This can includes screening for speech, vision or hearing problems. It can also include working with teachers to deliver health education about topics such as vaping and respectful relationships.

    Read more:
    Vaping and behaviour in schools: what does the research tell us?

Nurses as a bridge between two worlds

    • School nurses are the bridge between health and education: while well informed about the health system, they also have insight into how complex schools and classrooms can be.
    • School nurses can help young people be - and stay - at school.
    • School nurses can also be advocates for children, and help them beyond the school gates.

We need more information

    • Despite the many benefits, we don’t know exactly how many school nurses there are, or even how many students they provide care to as this information isn’t publicly available.
    • Some sources suggest there are approximately 1,500 school nurses in Australia but this is likely to be an underestimate.
    • With the school reform agreement there is a major opportunity to improve health services to students by improving their access to school nurses.

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

Retrieved on: 
Monday, June 26, 2023

The article can be accessed via the following link: https://authors.elsevier.com/sd/article/S2589537023002134 .

Key Points: 
  • The article can be accessed via the following link: https://authors.elsevier.com/sd/article/S2589537023002134 .
  • “Results from RESCUE-ALS study were important because they provided the first insights about the clinical benefits of CNM-Au8 in ALS patients and the duration of treatment required to detect them,” said Professor Steve Vucic, PhD, DSc, Northcott Chair of Neurology, The University of Sydney, and a co-investigator of the RESCUE-ALS study.
  • “The treatment effect demonstrated a clear survival signal associated with CNM-Au8 treatment and evidence for delayed clinical worsening morbidity events such as tracheostomy and initiation of feeding tube during the double-blind placebo-controlled period.
  • “We plan to report long-term follow-up data from this program later this year and meet with the FDA in the third quarter to identify next steps for our ALS program.”

RestorixHealth Announces Expansion of Post-Acute Clinical Services Team

Retrieved on: 
Thursday, June 1, 2023

RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce the expansion of its Post-Acute Clinical Services Team to offer customized support solutions in addition to the product support and cost avoidance program their customers have come to expect.

Key Points: 
  • RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce the expansion of its Post-Acute Clinical Services Team to offer customized support solutions in addition to the product support and cost avoidance program their customers have come to expect.
  • This expansion will include many new jobs involving sales, service, marketing, technology, training and education.
  • In response to market demands, one way the company is enhancing its service level is by introducing key role additions to its clinical team.
  • Along with their field-based Clinical Specialists, the team will now include Onboarding Specialists, an Inside Clinical & Service Team and an on-demand Virtual Clinical Support Team.